1
|
Miyahara H, Kubota N, Furuta J, Iijima S, Nomura T. Novel disinfectant olanexidine gluconate induced contact dermatitis. J Eur Acad Dermatol Venereol 2023. [PMID: 37016966 DOI: 10.1111/jdv.19097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2022] [Accepted: 03/28/2023] [Indexed: 04/06/2023]
Affiliation(s)
- H Miyahara
- Department of Dermatology Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | - N Kubota
- Department of Dermatology Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | - J Furuta
- Department of Dermatology Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | - S Iijima
- Division of Dermatology, Hanamizuki Clinic, Ushiku, Ibaraki, Japan
- Department of Dermatology, Ryugasaki Saiseikai Hospital, Ryugasaki, Ibaraki, Japan
| | - T Nomura
- Department of Dermatology Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| |
Collapse
|
2
|
Fujiwara N, Kubota N, Zhu S, Nakagawa S, Baba H, Hoshida Y. Disseminative Recurrence Signature for Hepatocellular Carcinoma From Nonalcoholic Fatty Liver Disease. Gastro Hep Adv 2023; 2:681-683. [PMID: 37621719 PMCID: PMC10448704 DOI: 10.1016/j.gastha.2023.03.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 08/26/2023]
Affiliation(s)
- N Fujiwara
- Division of Digestive and Liver Diseases, Department of Internal Medicine, Liver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
- Department of Gastroenterology and Hepatology, Mie University, Tsu, Mie, Japan
| | - N Kubota
- Division of Digestive and Liver Diseases, Department of Internal Medicine, Liver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
| | - S Zhu
- Division of Digestive and Liver Diseases, Department of Internal Medicine, Liver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
| | - S Nakagawa
- Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
| | - H Baba
- Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
| | - Y Hoshida
- Division of Digestive and Liver Diseases, Department of Internal Medicine, Liver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
| |
Collapse
|
3
|
Abe K, Kitago M, Matsuda S, Shinoda M, Yagi H, Abe Y, Oshima G, Hori S, Endo Y, Yokose T, Miura E, Kubota N, Ueno A, Masugi Y, Ojima H, Sakamoto M, Kitagawa Y. Epstein-Barr virus-associated inflammatory pseudotumor variant of follicular dendritic cell sarcoma of the liver: a case report and review of the literature. Surg Case Rep 2022; 8:220. [PMID: 36484868 PMCID: PMC9733763 DOI: 10.1186/s40792-022-01572-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2022] [Accepted: 11/22/2022] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Follicular dendritic cell sarcoma is a rare stromal tumor with no standard treatment. However, some reports have revealed that follicular dendritic cell sarcoma has an inflammatory pseudotumor variant associated with Epstein-Barr virus infection that has a relatively good prognosis. In this report, we present a case of a resected inflammatory pseudotumor variant of follicular dendritic cell sarcoma of the liver, and have reviewed the literature on the clinicopathological, molecular, and genomic features of this tumor. CASE PRESENTATION The inflammatory pseudotumor variant of follicular dendritic cell sarcoma originates only in the liver or spleen, causes no symptoms, and is more common in middle-aged Asian women. It has no characteristic imaging features, which partially explains why the inflammatory pseudotumor variant of follicular dendritic cell sarcoma is difficult to diagnose. Pathologically, the inflammatory pseudotumor variant of follicular dendritic cell sarcoma has spindle cells mixed with inflammatory cells and is variably positive for follicular dendritic cell markers (CD21, CD23, and CD35) and Epstein-Barr virus-encoded RNA. On genetic analysis, patients with this tumor high levels of latent membrane protein 1 gene expression and extremely low levels of host C-X-C Chemokine Receptor type 7 gene expression, indicating that the inflammatory pseudotumor variant of follicular dendritic cell sarcoma has a latent Epstein-Barr virus type 2 infection. CONCLUSIONS The inflammatory pseudotumor variant of follicular dendritic cell sarcoma is an Epstein-Barr virus-associated tumor and a favorable prognosis by surgical resection, similar to Epstein-Barr virus-associated gastric cancer.
Collapse
Affiliation(s)
- K. Abe
- grid.26091.3c0000 0004 1936 9959Department of Surgery, Keio University School of Medicine, Shinanomachi 35, Shinjuku-Ku, Tokyo, 160-8582 Japan
| | - M. Kitago
- grid.26091.3c0000 0004 1936 9959Department of Surgery, Keio University School of Medicine, Shinanomachi 35, Shinjuku-Ku, Tokyo, 160-8582 Japan
| | - S. Matsuda
- grid.26091.3c0000 0004 1936 9959Department of Surgery, Keio University School of Medicine, Shinanomachi 35, Shinjuku-Ku, Tokyo, 160-8582 Japan
| | - M. Shinoda
- grid.26091.3c0000 0004 1936 9959Department of Surgery, Keio University School of Medicine, Shinanomachi 35, Shinjuku-Ku, Tokyo, 160-8582 Japan
| | - H. Yagi
- grid.26091.3c0000 0004 1936 9959Department of Surgery, Keio University School of Medicine, Shinanomachi 35, Shinjuku-Ku, Tokyo, 160-8582 Japan
| | - Y. Abe
- grid.26091.3c0000 0004 1936 9959Department of Surgery, Keio University School of Medicine, Shinanomachi 35, Shinjuku-Ku, Tokyo, 160-8582 Japan
| | - G. Oshima
- grid.26091.3c0000 0004 1936 9959Department of Surgery, Keio University School of Medicine, Shinanomachi 35, Shinjuku-Ku, Tokyo, 160-8582 Japan
| | - S. Hori
- grid.26091.3c0000 0004 1936 9959Department of Surgery, Keio University School of Medicine, Shinanomachi 35, Shinjuku-Ku, Tokyo, 160-8582 Japan
| | - Y. Endo
- grid.26091.3c0000 0004 1936 9959Department of Surgery, Keio University School of Medicine, Shinanomachi 35, Shinjuku-Ku, Tokyo, 160-8582 Japan
| | - T. Yokose
- grid.26091.3c0000 0004 1936 9959Department of Surgery, Keio University School of Medicine, Shinanomachi 35, Shinjuku-Ku, Tokyo, 160-8582 Japan
| | - E. Miura
- grid.26091.3c0000 0004 1936 9959Department of Pathology, Keio University School of Medicine, Tokyo, Japan
| | - N. Kubota
- grid.26091.3c0000 0004 1936 9959Department of Pathology, Keio University School of Medicine, Tokyo, Japan
| | - A. Ueno
- grid.26091.3c0000 0004 1936 9959Department of Pathology, Keio University School of Medicine, Tokyo, Japan
| | - Y. Masugi
- grid.26091.3c0000 0004 1936 9959Department of Pathology, Keio University School of Medicine, Tokyo, Japan
| | - H. Ojima
- grid.26091.3c0000 0004 1936 9959Department of Pathology, Keio University School of Medicine, Tokyo, Japan
| | - M. Sakamoto
- grid.26091.3c0000 0004 1936 9959Department of Pathology, Keio University School of Medicine, Tokyo, Japan
| | - Y. Kitagawa
- grid.26091.3c0000 0004 1936 9959Department of Surgery, Keio University School of Medicine, Shinanomachi 35, Shinjuku-Ku, Tokyo, 160-8582 Japan
| |
Collapse
|
4
|
Inoue K, Shiozaki M, Sasaki S, Sasaki Y, Tamura H, Fukuda K, Kubota N, Hiki M, Funamizu T, Sumiyoshi M, Minamino T. Determination of physiological cardiac myosin-binging protein levels (cMyc) in healthy populations. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Cardiac myosin–binding protein C (cMyC) is a cardiac-restricted protein that has more abundant, rapid release and clearance kinetics than cardiac troponin. The current ESC guideline suggests the cMyC may provide value as an alternative to cardiac troponin. The 99th percentile value is universally endorsed as the reference cut off to aid in the diagnosis of acute myocardial infarction (AMI), however, none of the report of healthy population of cMyC.
Purpose
The aim of this study was to evaluate the distribution of cMyC values in healthy subjects.
Methods
We used two cohorts in this retrospective study. 1) Healthy subjects; a total of 500 subjects (250 men and 250 women) who had annual health examinations in 2012 in the area of Kamigoto, a suburb of Nagasaki city in Southern Japan were enrolled. All participants showed none of abnormal findings including cell blood counts, chemical analysis, liver function tests, general urine tests, occult blood tests of stool, barium swallow, mammography for women, abdominal ultrasound sonography, and electrocardiogram. All blood samples were obtained in a fasting state in the morning. 2) Chest pain subjects; we collected samples from 250 subjects including 50 with non-ST elevation myocardial infarction visited admitted to a university hospital for measurement of high-sensitivity troponin T and coronary artery assessment by coronary angiography. We measured cMyC level in both cohorts by HISCL™-800 system (Sysmex corporation, Japan). The assay has a limit of detection of 0.5 ng/L and a lower limit of quantification of 1.3 ng/L.
Result
In healthy subjects, median age (IQR) was 44 (20, 82) in men and 50 (23, 91) in women. The 99th percentile of cMyC was 27.3 ng/L, which was around one-third lower than that in previous report (87 ng/L). In chest pain subjects, the concentrations of cMyC at presentation were significantly higher in those with versus without AMI (median, 66 ng/L versus 10 ng/L, P<0.001). Discriminatory power for AMI, as quantified by the area under the receiver-operating characteristic curve (AUC), was comparable for cMyC (AUC, 0.85 (95% CI 0.79–0.91) and hs-cTnT (AUC, 0.81 (95% CI 0.76–0.88)).
Conclusion
We defined the normal range of cMyC in healthy Japanese subjects. The level of cMyC at presentation provides discriminatory power comparable to hs-cTnT in the diagnosis of AMI. To determine the physiological value of a biomarker may be necessary to evaluate enough information about their health status.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Grant-in-Aid for Scientific Research
Collapse
Affiliation(s)
- K Inoue
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - M Shiozaki
- Tokyo Metropolitan Tama Medical Center, Cardiology, Tokyo, Japan
| | - S Sasaki
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - Y Sasaki
- Sysmex R&D Center Europe GmbH, Hamburg, Germany
| | - H Tamura
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - K Fukuda
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - N Kubota
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - M Hiki
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - T Funamizu
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - M Sumiyoshi
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - T Minamino
- Juntendo University School of Medicine, Tokyo, Japan
| |
Collapse
|
5
|
Moline M, Thein S, Bsharat M, Rabbee N, Kemethofer-Waliczky M, Filippov G, Kubota N, Dhadda S. Safety and Efficacy of Lemborexant in Patients With Irregular Sleep-Wake Rhythm Disorder and Alzheimer's Disease Dementia: Results From a Phase 2 Randomized Clinical Trial. J Prev Alzheimers Dis 2020; 8:7-18. [PMID: 33336219 DOI: 10.14283/jpad.2020.69] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND Irregular sleep-wake rhythm disorder (ISWRD) is a common sleep disorder in individuals with Alzheimer's disease dementia (AD-D). OBJECTIVES This exploratory phase 2 proof-of-concept and dose-finding clinical trial evaluated the effects of lemborexant compared with placebo on circadian rhythm parameters, nighttime sleep, daytime wakefulness and other clinical measures of ISWRD in individuals with ISWRD and mild to moderate AD-D. DESIGN Multicenter, randomized, double-blind, placebo-controlled, parallel-group study. SETTING Sites in the United States, Japan and the United Kingdom. PARTICIPANTS Men and women 60 to 90 years of age with documentation of diagnosis with AD-D and Mini-Mental State Exam (MMSE) score 10 to 26. INTERVENTION Subjects were randomized to placebo or one of four lemborexant treatment arms (2.5 mg, 5 mg, 10 mg or 15 mg) once nightly at bedtime for 4 weeks. MEASUREMENTS An actigraph was used to collect subject rest-activity data, which were used to calculate sleep-related, wake-related and circadian rhythm-related parameters. These parameters included least active 5 hours (L5), relative amplitude of the rest-activity rhythm (RA) and mean duration of sleep bouts (MDSB) during the daytime. The MMSE and the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) were used to assess for changes in cognitive function. RESULTS Sixty-two subjects were randomized and provided data for circadian, daytime and nighttime parameters (placebo, n = 12; lemborexant 2.5 mg [LEM2.5], n = 12; lemborexant 5 mg [LEM5], n = 13, lemborexant 10 mg [LEM10], n = 13 and lemborexant 15 mg [LEM15], n = 12). Mean L5 showed a decrease from baseline to week 4 for LEM2.5, LEM5 and LEM15 that was significantly greater than with placebo (all p < 0.05), suggesting a reduction in restlessness. For RA, LS mean change from baseline to week 4 versus placebo indicated greater distinction between night and day with all dose levels of lemborexant, with significant improvements seen with LEM5 and LEM15 compared with placebo (both p < 0.05). The median percentage change from baseline to week 4 in MDSB during the daytime indicated a numerical decrease in duration for LEM5, LEM10 and LEM15, which was significantly different from placebo for LEM5 and LEM15 (p < 0.01 and p = 0.002, respectively). There were no serious treatment-emergent adverse events or worsening of cognitive function, as assessed by the MMSE and ADAS-Cog. Lemborexant was well tolerated. No subjects discontinued treatment. CONCLUSIONS This study provides preliminary evidence of the potential utility of lemborexant as a treatment to address both nighttime and daytime symptoms in patients with ISWRD and AD-D.
Collapse
Affiliation(s)
- M Moline
- Margaret Moline, PhD, Clinical Research, Eisai, Inc., 100 Tice Boulevard, Woodcliff Lake, NJ 07677, USA, Phone: +1 (201) 949-4226, Fax: +1 (201) 949-4595, E-mail:
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Shiozaki M, Inoue K, Suwa S, Lee C, Chiang S, Fukuda K, Hiki M, Kubota N, Tamura H, Fujiwara Y, Miyazaki T, Hirano Y, Sumiyoshi M. One-year outcome of the rule-out group according to the 0-h /1-hour algorithm with suspected myocardial infarction in Asian countries. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background/Introduction; A rapid rule-out or rule-in protocol based on the 0-h/1-hour algorithm using high-sensitivity cardiac troponin T (hs-cTnT) is recommended by the European Society of Cardiology (ESC). Around 40–50% were stratified into “rule-out” group, and their 30-days prognosis was excellent. However, the one-year prognosis is uncertain. We aimed to better characterize these patients.
Methods
This study was a prospective, multi-center, observational study of patients with suspected non-ST elevation acute coronary syndrome (NSTE-ACS) admitted to 5 hospitals in Japan and Taiwan from 2014 November to 2018 December, respectively.
All patients underwent a clinical assessment the included medical history, physical examination, 12-lead ECG, standard blood test, chest radiography. Exclusion criteria were ST elevated myocardial infarction, chronic kidney disease (serum creatinine more than 3 mg/dL) and congestive heart failure, arrhythmia, or infection disease. The patients were divided into three groups according to the algorithm; “rule-out”, “observe” and “rule-in”. The final diagnosis was then adjudicated by 2 independent cardiologists using all available information, including coronary angiography, coronary computed tomography, stress electrocardiography and follow-up data. The presence of acute myocardial infarction (AMI) was defined according to the Fourth Universal Definition of Myocardial Infarction. After hospital discharge patients were follow after one-year b telephone or in written form. Major adverse cardiovascular events (including death myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention (PCI)) were recorded by establishing contact with the patient and the family physicians. The primary prognosis end point was all-cause mortality.
Results
Of the 1,187 patients were analyzed after exclusion. The prevalence rate of AMI was 16.1%. According to the algorithm, 42% (n=493) of patients were assigned to “rule-out” group and had no AMI nor death. The most common final adjudicated diagnoses were atypical chest pain (80%), gallstone attack (3%) and vasospastic angina pectoris (2%). All patients with unstable angina (4.7%) underwent PCI.
Conclusion(s)
Our findings suggest that the “rule-out” group patients according to ESC 0-h/1-hour algorithm provides very high safety and efficacy for the triage toward AMI.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- M Shiozaki
- Juntendo University Nerima Hospital, Cardiology, Tokyo, Japan
| | - K Inoue
- Juntendo University Nerima Hospital, Cardiology, Tokyo, Japan
| | - S Suwa
- Juntendo University Shizuoka Hospital, Cardiology, Izunokuni, Japan
| | - C.C Lee
- National Taiwan University Hospital, Emergency Medicine, Taipei, Taiwan
| | - S.J Chiang
- Taipei City Hospital, Cardiology, Taipei, Taiwan
| | - K Fukuda
- Juntendo University Nerima Hospital, Cardiology, Tokyo, Japan
| | - M Hiki
- Juntendo University Nerima Hospital, Cardiology, Tokyo, Japan
| | - N Kubota
- Juntendo University Nerima Hospital, Cardiology, Tokyo, Japan
| | - H Tamura
- Juntendo University Nerima Hospital, Cardiology, Tokyo, Japan
| | - Y Fujiwara
- Juntendo University Nerima Hospital, Cardiology, Tokyo, Japan
| | - T Miyazaki
- Juntendo University Urayasu Hospital, Cardiology, Chiba, Japan
| | - Y Hirano
- Juntendo University Urayasu Hospital, Emergency and Critical Care Medicine, Chiba, Japan
| | - M Sumiyoshi
- Juntendo University Nerima Hospital, Cardiology, Tokyo, Japan
| |
Collapse
|
7
|
Okiyama N, Nakamura Y, Ishitsuka Y, Inoue S, Kubota N, Saito A, Watanabe R, Fujisawa Y, Igawa K. Successful topical treatment with ketoconazole for facial rashes refractory to dupilumab in patients with atopic dermatitis: case reports. J Eur Acad Dermatol Venereol 2020; 34:e474-e476. [DOI: 10.1111/jdv.16383] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2020] [Revised: 02/29/2020] [Accepted: 03/16/2020] [Indexed: 12/20/2022]
Affiliation(s)
- N. Okiyama
- Department of Dermatology Faculty of Medicine University of Tsukuba Ibaraki Japan
| | - Y. Nakamura
- Department of Dermatology Faculty of Medicine University of Tsukuba Ibaraki Japan
| | - Y. Ishitsuka
- Department of Dermatology Faculty of Medicine University of Tsukuba Ibaraki Japan
| | - S. Inoue
- Department of Dermatology Faculty of Medicine University of Tsukuba Ibaraki Japan
| | - N. Kubota
- Department of Dermatology Faculty of Medicine University of Tsukuba Ibaraki Japan
| | - A. Saito
- Department of Dermatology Faculty of Medicine University of Tsukuba Ibaraki Japan
| | - R. Watanabe
- Department of Dermatology Faculty of Medicine University of Tsukuba Ibaraki Japan
| | - Y. Fujisawa
- Department of Dermatology Faculty of Medicine University of Tsukuba Ibaraki Japan
| | - K. Igawa
- Department of Dermatology Dokkyo Medical University School of Medicine Tochigi Japan
| |
Collapse
|
8
|
Moline M, Inoue Y, Kubota N, Pinner K, Perdomo C, Yardley J. 0486 Impact of Intrinsic Factors on Efficacy of Lemborexant: Subgroup Analyses of SUNRISE-2. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Lemborexant (LEM), a dual orexin receptor antagonist, demonstrated significant benefits vs placebo on patient-reported sleep outcomes in adults age ≥18y in SUNRISE-2 (NCT02952820; E2006-G000-303). The impact of intrinsic factors (sex, race, and region) on LEM efficacy outcomes was assessed.
Methods
SUNRISE-2 was a randomized, double-blind, global phase 3 study in adults age ≥18y with insomnia disorder (Full Analysis Set, n=949). Subjects received placebo (n=318) or LEM (5mg [LEM5], n=316; 10mg [LEM10]; n=315) for 6 months. At 6 months, placebo subjects were rerandomized to LEM for another 6 months (not reported here); LEM subjects remained on their assigned dose. Sleep diary-based (subjective) sleep onset latency (sSOL) and wake after sleep onset (sWASO) were assessed for prespecified patient subgroups including: sex (male [n=302], female [n=647]), race (white [n=679], black [n=76], Asian [n=178]), and region (North America [n=302], Europe/New Zealand [n=483], Asia [n=164]). Analyses were not controlled for multiplicity.
Results
LEM5 and LEM10 provided numerically greater median reductions (improvement) from baseline in sSOL vs placebo at 6 months in across all subgroups examined. Also, LEM5 and LEM10 led to mean reductions (improvement) from baseline at 6 months in sWASO for all subgroups. While several subgroups had small numbers of subjects, changes from baseline in sSOL and sWASO were in the direction of improvement in the majority of subgroups. Pharmacokinetic analyses showed no important differences in exposure by these factors.
Conclusion
LEM treatment demonstrated efficacy in improving sSOL and sWASO across patient subgroups, supporting common dosing instructions for both sexes and all races.
Support
Eisai Inc.
Collapse
Affiliation(s)
| | - Y Inoue
- Tokyo Medical University, Tokyo, JAPAN
| | | | - K Pinner
- Eisai Ltd., Hatfield, UNITED KINGDOM
| | | | - J Yardley
- Eisai Ltd., Hatfield, UNITED KINGDOM
| |
Collapse
|
9
|
Moline M, Inoue Y, Pinner K, Perdomo C, Filippov G, Kubota N, Yardley J. 0474 Long-Term Efficacy and Safety of Lemborexant in Elderly Adults with Insomnia Disorder: Results from SUNRISE-2. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.471] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
In SUNRISE-2 (NCT02952820; E2006-G000-303), the dual orexin receptor antagonist lemborexant (LEM) demonstrated significant benefit versus placebo (PBO) on subjective sleep endpoints over 6mo in subjects age ≥18y; benefits were sustained over 12mo. Here we present 12mo efficacy and safety data for LEM from the elderly (≥65y) subgroup.
Methods
SUNRISE-2 was a 12mo, randomized, double-blind, PBO-controlled (first 6mo [Period 1]), global phase 3 study. During Period 1, subjects were randomized to PBO or LEM (5mg, [LEM5]; 10mg, [LEM10]). During Period 2 (second 6mo), LEM subjects continued their assigned dose while PBO subjects were rerandomized to LEM5 or LEM10 (not reported here). Patient-reported (subjective) sleep endpoints were assessed from sleep diary data (sleep onset latency [sSOL]; sleep efficiency [sSE]; wake after sleep onset [sWASO]).
Results
Of the 949 subjects in the Full Analysis Set, 262 were age ≥65y. At 6mo, in subjects ≥65y, median sSOL significantly decreased from baseline for LEM5 (−21.7) and LEM10 (−26.0) versus PBO (−10.8; P<0.0001, P<0.01, respectively). At 12mo, LEM5 and LEM10 subjects maintained decreases in median sSOL (−29.3, −34.3, respectively). At 6mo, the mean (SD) increase from baseline in sSE was significantly larger versus PBO (8.5[13.3]) for LEM5 (16.9[13.6]; P<0.001) and LEM10 (14.9[15.9]; P<0.01). At 12mo, mean (SD) increase in sSE was maintained for LEM5 (18.1[12.5]) and LEM10 (18.0[16.8]). At 6mo, mean (SD) change from baseline in sWASO was significantly decreased versus PBO (−26.5 [52.9]) for LEM5 and LEM10 (−54.8[64.4], P<0.01; −51.4[69.3], P<0.05, respectively). At 12mo, mean (SD) decrease in sWASO was maintained for LEM5 (−58.6[46.0]) and LEM10 (−60.9[80.4]). Over 12mo, the most common (>10% either group) treatment emergent adverse events with LEM5 and LEM10, respectively, were somnolence (9.3%, 19.0%), nasopharyngitis (9.3%, 10.7%), and headache (10.5%, 6.0%).
Conclusion
In elderly subjects, LEM demonstrated efficacy at 6mo, which persisted at 12mo; LEM was well tolerated.
Support
Eisai Inc.
Collapse
Affiliation(s)
| | - Y Inoue
- Tokyo Medical University, Tokyo, JAPAN
| | - K Pinner
- Eisai Ltd., Hatfield, UNITED KINGDOM
| | | | | | | | - J Yardley
- Eisai Ltd., Hatfield, UNITED KINGDOM
| |
Collapse
|
10
|
Yardley J, Inoue Y, Pinner K, Perdomo C, Filippov G, Kubota N, Moline M. 0473 Effectiveness and Safety of Lemborexant in Subjects Previously Treated with Placebo for 6 Months in SUNRISE-2. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
In SUNRISE-2 (NCT02952820; E2006-G000-303), while lemborexant (LEM) provided significant benefit versus placebo (PBO) on sleep-diary measurements over 6mo, some improvement was noted in PBO subjects. We report outcomes from PBO subjects rerandomized to LEM during the last 6mo of SUNRISE-2.
Methods
SUNRISE-2 was a randomized, double-blind, global phase 3 study in adults (≥18y) with insomnia disorder. Subjects received PBO or LEM (5mg [LEM5]; 10mg [LEM10]) for 6mo. PBO subjects were rerandomized to LEM for another 6mo; LEM subjects continued assigned treatment. Changes from 6mo baseline (calculated after PBO completion) in subjective sleep onset latency (sSOL), subjective sleep efficiency (sSE), and subjective wake after sleep onset (sWASO) are reported for rerandomized subjects.
Results
At study baseline for PBO subjects (n=318), median sSOL (min) was 55.9, mean (SD) sSE (%) and sWASO (min) were 61.3 (17.8) and 132.5 (80.2), respectively. The 6mo baseline values for rerandomized PBO-LEM5 (n=133) and PBO-LEM10 (n=125) subjects, respectively, were: median sSOL, 31.2, 34.3; mean (SD) sSE, 70.5 (20.2), 71.1 (18.0); mean (SD) sWASO, 105.1 (80.6), 100.1 (84.6). Median sSOL decreased from the 6mo baseline after 1mo (PBO-LEM5, −3.2; PBO-LEM10, −2.9) and 6mo (PBO-LEM5, −2.7; PBO-LEM10, −5.0). Mean (SD) sSE increased from the 6mo baseline after 1mo (PBO-LEM5, 3.9 [12.1]; PBO-LEM10, 3.5 [8.1]) and 6mo (PBO-LEM5, 3.9 [13.6]; PBO-LEM10, 4.5 [13.0]). Mean (SD) sWASO decreased after 1mo (PBO-LEM5, −8.5 [49.4]; PBO-LEM10, −5.7 [36.1]) and 6mo (PBO-LEM5, −8.2 [49.0]; PBO-LEM10, −10.0 [58.8]). Treatment-emergent adverse events incidence was similar during PBO (62.7%) and LEM treatment (PBO-LEM5, 54.9%; PBO-LEM10, 57.7%). Adverse events were consistent with those seen in the initial 6mo of treatment for patients originally randomized to LEM.
Conclusion
Rerandomization to LEM was associated with additional improvement in sleep outcomes following the PBO-related response. LEM benefit was evident after 1mo and was sustained throughout treatment. LEM was well tolerated.
Support
Eisai Inc.
Collapse
Affiliation(s)
- J Yardley
- Eisai Ltd., Hatfield, UNITED KINGDOM
| | - Y Inoue
- Tokyo Medical University, Tokyo, JAPAN
| | - K Pinner
- Eisai Ltd., Hatfield, UNITED KINGDOM
| | | | | | | | | |
Collapse
|
11
|
Yardley J, Kärppä M, Inoue Y, Pinner K, Perdomo C, Filippov G, Kubota N, Moline M. Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: 12-month results from sunrise-2. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.736] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Shiozaki M, Inoue K, Suwa S, Lee CC, Chiang SJ, Shimizu M, Fukuda K, Hiki M, Kubota N, Tamura H, Fujiwara Y, Sumiyoshi M, Daida H. P2677A combination of HEART score and a 0-hour/1-hour algorithm for early and safe triage tool for patients in observe zone. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The European Society Cardiology guidelines recommend that a 0-hour/1-hour (0–1hr) algorithm using high sensitivity cardiac troponin T (hs-cTnT) improves the early triage of patients with suspected non-ST elevation acute coronary syndrome (NSTE-ACS). However, diagnostic uncertainty remains in the 25–30% of patients assigned to “observe” group.
Purpose
To establish a step wise risk score system using HEART score and 0-hour/1-hour algorithm to identify the low risk group from observation group.
Methods
This study was a prospective, multi-center, observational study of patients with suspected NSTE-ACS admitted to five hospitals in Japan and Taiwan from 2014 to 2018, respectively. We applied the algorithm and calculated HEART score simultaneously. Patients were divided into three groups according to the algorithm: hs-cTnT below 12 ng/L and delta 1 hour below 3 ng/L were the “rule out” group; hs-cTnT at least 52 ng/L or delta 1 hour at least 5 ng/L were in the “rule in” group; the remaining patients were classified as the “observe” group. All patients underwent a clinical assessment the included medical history, physical examination, 12-lead ECG, continuous ECG monitoring, pulse oximetry, standard blood test, chest radiography, cardiac and abdominal ultrasonography. Patients presenting with congestive heart failure, terminal kidney disease on hemodialysis state, arrhythmia, or infection disease (which causes to increase troponin level) were excluded. Thirty-day MACE was defined as acute myocardial infarction, unstable angina (UA), or death.
Results
Of the 1,332 patients enrolled, 933 patients were analyzed after exclusion. NSTE-ACS was the final diagnosis for 122 (13.1%) patients and none of death. The HEART score less than 4 points in observation groups identified as very low risk with a negative predictive value (NPV) of 98.1% (95% confidential interval (CI); 90.1%-100%) and sensitivity of 98.0% (95% CI; 89.6%-100%). There were only one patient (0.5%) with AMI. In case of the HEART score less than 5 points, it could also identify as very low risk with a NPV of 96.7% (95% CI; 90.8%-99.3%%) and sensitivity of 94.1% (95% CI; 83.8%-98.8%). There were only three patients (1.2%) with AMI.
Conclusion
A combination of HEART score and the 0-hour/1-hour algorithm strategy rapidly identified the patient in observation group of 30-day MACE including UA where nor further cardiac testing would be needed.
Acknowledgement/Funding
JSPS KAKENHI Grant Number JP18K09554
Collapse
Affiliation(s)
- M Shiozaki
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - K Inoue
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - S Suwa
- Juntendo University Shizuoka Hospital, Cardiology, Shizuoka, Japan
| | - C C Lee
- National Taiwan University Hospital, Emergency Medicine, Taipei, Taiwan
| | | | - M Shimizu
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - K Fukuda
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - M Hiki
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - N Kubota
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - H Tamura
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - Y Fujiwara
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - M Sumiyoshi
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - H Daida
- Juntendo University School of Medicine, Tokyo, Japan
| |
Collapse
|
13
|
Shiozaki M, Inoue K, Suwa S, Lee CC, Chiang SJ, Shimizu M, Fukuda K, Hiki M, Kubota N, Tamura H, Fujiwara Y, Sumiyoshi M, Daida H. P2676Prospective validation of the 2015 ESC 0-hour/1-hour algorithm using high-sensitivity cardiac troponin T in Asian countries. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background/Introduction
Implementation of the 2015 ESC 0-hour/1-hour algorithm using high-sensitivity troponin (hs-cTn) T in Asian countries presents a challenge for clinical practice.
Purpose
We aimed to prospectively validate the 0-hour/1-hour algorithm in Asian countries.
Methods
We conducted a prospective, multi-center, international cohort already utilizing 0-hour/1-hour algorithm using hs-cTnT for evaluation of patients with suspected of non-ST elevation acute coronary syndrome (NSTE-ACS). All patients underwent a clinical assessment the included medical history, physical examination, 12-lead ECG, continuous ECG monitoring, pulse oximetry, standard blood test, chest radiography, cardiac and abdominal ultrasonography. Patients presenting with congestive heart failure, terminal kidney disease on hemodialysis state, arrhythmia, or infection disease (which cause to increase troponin level) were excluded. Patients were divided into three groups according to the algorithm: hs-cTnT below 12 ng/L and delta 1 hour below 3 ng/L were the “rule out” group; hs-cTnT at least 52 ng/L or delta 1 hour at least 5 ng/L were in the “rule in” group; the remaining patients were classified as the “observational” group. The final diagnosis was then adjudicated by 2 independent cardiologists using all available information, including coronary angiography, coronary computed tomography, stress electrocardiography and follow-up data. The presence of acute myocardial infarction (AMI) was defined according to the Fourth Universal Definition of Myocardial Infarction.
Results
Of the 1,332 patients enrolled in 2014 to 2018, 933 patients were analyzed after exclusion. AMI was the final diagnosis for 122 (13.1%) patients. The algorithm ruled out AMI in 401 patients with a negative predictive value and sensitivity of 100% (95% confidential interval [CI], 98.6%-100%) and 100% (95% CI, 94.0%-100%), respectively, in the rule-out group. None of the patients were diagnosed with AMI. Among the 211 patients classified into the rule-in group, 90 were diagnosed as having AMI. The positive predictive value and specificity were 43.1% (95% CI, 36.2%-50.2%) and 78.3% (95% CI, 74.5%-81.7%), respectively. The median length of hospital stay was 159 min (142–180) in rule out group.
Conclusion(s)
Our findings suggest that the 0-hour/1-hour algorithm using hs-cTnT provides very high safety and efficacy for the triage toward rapid rule-out to rule-in of AMI.
Acknowledgement/Funding
JSPS KAKENHI Grant Number JP18K09554
Collapse
Affiliation(s)
- M Shiozaki
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - K Inoue
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - S Suwa
- Juntendo University Shizuoka Hospital, Cardiology, Shizuoka, Japan
| | - C C Lee
- National Taiwan University Hospital, Emergency Medicine, Taipei, Taiwan
| | | | - M Shimizu
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - K Fukuda
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - M Hiki
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - N Kubota
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - H Tamura
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - Y Fujiwara
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - M Sumiyoshi
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - H Daida
- Juntendo University School of Medicine, Tokyo, Japan
| |
Collapse
|
14
|
Yamaguchi M, Suzuki R, Oguchi M, Miyazaki K, Taguchi S, Amaki J, Maeda T, Kubota N, Maruyama D, Terui Y, Sekiguchi N, Takizawa J, Tsukamoto H, Murayama T, Ando T, Matsuoka H, Hasegawa M, Wada H, Sakai R, Kameoka Y, Tsukamoto N, Choi I, Masaki Y, Shimada K, Fukuhara N, Utsumi T, Uoshima N, Kagami Y, Asano N, Katayama N. CLINICAL OUTCOMES AND DIAGNOSIS-TO-TREATMENT INTERVAL IN PATIENTS WITH NK/T-CELL LYMPHOMA: 7-YEAR FOLLOW-UP OF THE NKEA STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.86_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Yamaguchi
- Department of Hematology and Oncology; Mie University Graduate School of Medicine; Tsu Japan
| | - R. Suzuki
- Oncology and Hematology; Shimane University Hospital; Izumo Japan
| | - M. Oguchi
- Radiation Oncology; Cancer Institute Hospital of Japanese Foundation for Cancer Research; Tokyo Japan
| | - K. Miyazaki
- Department of Hematology and Oncology; Mie University Graduate School of Medicine; Tsu Japan
| | - S. Taguchi
- Radiation Oncology; Cancer Institute Hospital of Japanese Foundation for Cancer Research; Tokyo Japan
| | - J. Amaki
- Hematology and Oncology; Tokai University School of Medicine; Kanagawa Japan
| | - T. Maeda
- Hematology; Kurashiki Central Hospital; Kurashiki Japan
| | - N. Kubota
- Hematology; Saitama Cancer Center; Ina Japan
| | - D. Maruyama
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - Y. Terui
- Hematology Oncology; Cancer Institute Hospital of Japanese Foundation for Cancer Research; Tokyo Japan
| | - N. Sekiguchi
- Comprehensive Cancer Therapy; Shinshu University School of Medicine; Matsumoto Japan
| | - J. Takizawa
- Hematology; Endocrinology and Metabolism, Niigata University Faculty of Medicine; Niigata Japan
| | - H. Tsukamoto
- Hematology; Showa University School of Medicine; Tokyo Japan
| | - T. Murayama
- Hematology; Hyogo Cancer Center; Akashi Japan
| | - T. Ando
- Hematology; Respiratory Medicine and Oncology, Saga University; Saga Japan
| | - H. Matsuoka
- Medical Oncology/Hematology; Kobe University; Kobe Japan
| | - M. Hasegawa
- Radiation Oncology; Nara Medical University; Kashihara Japan
| | - H. Wada
- Hematology; Kawasaki Medical School; Kurashiki Japan
| | - R. Sakai
- Medical Oncology; Kanagawa Cancer Center; Yokohama Japan
| | - Y. Kameoka
- Hematology; Nephrology and Rheumatology, Akita University; Akita Japan
| | - N. Tsukamoto
- Oncology Center; Gunma University Hospital; Maebashi Japan
| | - I. Choi
- Hematology; National Hospital Organization Kyushu Cancer Center; Fukuoka Japan
| | - Y. Masaki
- Hematology and Immunology; Kanazawa Medical University; Kanazawa Japan
| | - K. Shimada
- Hematology and Oncology; Nagoya University School of Medicine; Nagoya Japan
| | - N. Fukuhara
- Hematology & Rheumatology; Tohoku University School of Medicine; Sendai Japan
| | - T. Utsumi
- Hematology; Shiga Medical Center for Adults; Moriyama Japan
| | - N. Uoshima
- Hematology; Japanese Red Cross Kyoto Daini Hospital; Kyoto Japan
| | - Y. Kagami
- Hematology; Toyota Kosei Hospital; Toyota Japan
| | - N. Asano
- Molecular Diagnostics; Shinshu Medical Center; Suzaka Japan
| | - N. Katayama
- Department of Hematology and Oncology; Mie University Graduate School of Medicine; Tsu Japan
| |
Collapse
|
15
|
Kubota N, Saito A, Tanaka R, Clausen B, Fujimoto M, Okiyama N. 018 Langerhans cells suppress CD8 T cells in situ during acute graft-versus-host disease-like autoimmune mucocutaneous disease. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
16
|
Onishi Y, Eshita Y, Ji RC, Kobayashi T, Onishi M, Mizuno M, Yoshida J, Kubota N. A robust control system for targeting melanoma by a supermolecular DDMC/paclitaxel complex. Integr Biol (Camb) 2018; 10:549-554. [PMID: 30140840 DOI: 10.1039/c8ib00071a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A DEAE-dextran-MMA copolymer (DDMC)-paclitaxel (PTX) conjugate was prepared using PTX as the guest and DDMC as the host. The resistance of B16F10 melanoma cells to PTX was confirmed, while the DDMC-PTX conjugate showed excellent anticancer activity that followed the Hill equation. The robustness in the tumor microenvironment of the allosteric system was confirmed via BIBO stability. This feedback control system, explained via a transfer function, was very stable and showed the sustainability of the system via a loop, and it showed superior anti-cancer activity without drug resistance from cancer cells. The block diagram of this signal system in the tumor microenvironment used its loop transfer function G(s) and the dN(s) of the external force. This indicial response is an ideal one without a time lag for the outlet response. The cell death rate of DDMC-PTX is more dependent on the Hill coefficient n than on the Michaelis constant Km. This means that this supermolecular reaction with tubulin follows an "induced fit model".
Collapse
Affiliation(s)
- Y Onishi
- Ryujyu Science Corporation, 39-4 Kosora-cho, Seto, Aichi 489-0842, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Yasui H, Kubota N, Nishizumi J, Sakai Y, Yamamori T, Inanami O. Preclinical study on hypoxic radiosensitizing effects of glycididazole in comparison with those of doranidazole in vitro and in vivo. Oncol Lett 2018; 15:1993-1998. [PMID: 29434899 DOI: 10.3892/ol.2017.7481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2017] [Accepted: 11/20/2017] [Indexed: 11/06/2022] Open
Abstract
To overcome the radioresistance of hypoxic cells in solid tumor, numerous types of radiosensitizers specifically against them have been developed. Glycididazole has a chemical structure in which two metronidazole forms are combined, and is widely used as a hypoxic radiosensitizer in China. However, a detailed investigation of its radiosensitizing properties has not been performed. The present study reported a comparative assessment of glycididazole and doranidazole, another hypoxic radiosensitizer. All experiments were performed using the murine squamous cell carcinoma cell line SCCVII. Prior to X-irradiation, the cells were treated with the test drugs at concentrations of 10 mM and 200 mg/kg in vitro and in vivo, respectively. Uptake and their intratumor chemical forms were analyzed by high performance liquid chromatography (HPLC). Both drugs enhanced the reproductive cell death induced by X-irradiation under hypoxia. However, the growth delay assay of the transplanted tumor revealed the combination of X-irradiation and glycididazole showed a similar antitumor effect to that of X-irradiation alone, whereas doranidazole significantly sensitized the cells to X-irradiation. HPLC analysis revealed that incorporated glycididazole was decomposed to metronidazole and was therefore present at a lower concentration compared with that of doranidazole. The decomposition of glycididazole to metronidazole reduced its radiosensitizing efficiency in vivo. Elucidation of the kinetics of drugs containing metabolizable chemical forms is necessary for the optimization of clinical treatment.
Collapse
Affiliation(s)
- Hironobu Yasui
- Laboratory of Radiation Biology, Department of Applied Veterinary Sciences, Division of Veterinary Medicine, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido 060-0818, Japan.,Central Institute of Isotope Science, Hokkaido University, Sapporo, Hokkaido 060-0815, Japan
| | - Nobuo Kubota
- R&D Laboratories, Pola Pharma Inc., Yokohama, Kanagawa 244-0812, Japan
| | - Junko Nishizumi
- R&D Laboratories, Pola Pharma Inc., Yokohama, Kanagawa 244-0812, Japan
| | - Yuri Sakai
- Laboratory of Radiation Biology, Department of Applied Veterinary Sciences, Division of Veterinary Medicine, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido 060-0818, Japan
| | - Tohru Yamamori
- Laboratory of Radiation Biology, Department of Applied Veterinary Sciences, Division of Veterinary Medicine, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido 060-0818, Japan
| | - Osamu Inanami
- Laboratory of Radiation Biology, Department of Applied Veterinary Sciences, Division of Veterinary Medicine, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido 060-0818, Japan
| |
Collapse
|
18
|
Kobayashi J, Yanagisawa R, Ono T, Tatsuzawa Y, Tokutake Y, Kubota N, Hidaka E, Sakashita K, Kojima S, Shimodaira S, Nakamura T. Administration of platelet concentrates suspended in bicarbonated Ringer's solution in children who had platelet transfusion reactions. Vox Sang 2017; 113:128-135. [DOI: 10.1111/vox.12608] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2017] [Revised: 09/19/2017] [Accepted: 09/24/2017] [Indexed: 02/06/2023]
Affiliation(s)
- J. Kobayashi
- Department of Laboratory Medicine; Nagano Children's Hospital; Azumino Japan
| | - R. Yanagisawa
- Life Science Research Center; Nagano Children's Hospital; Azumino Japan
- Division of Blood Transfusion; Shinshu University Hospital; Matsumoto Japan
- Center for Advanced Cell Therapy; Shinshu University Hospital; Matsumoto Japan
| | - T. Ono
- Department of Laboratory Medicine; Nagano Children's Hospital; Azumino Japan
| | - Y. Tatsuzawa
- Department of Laboratory Medicine; Nagano Children's Hospital; Azumino Japan
| | - Y. Tokutake
- Department of Laboratory Medicine; Nagano Children's Hospital; Azumino Japan
| | - N. Kubota
- Department of Laboratory Medicine; Nagano Children's Hospital; Azumino Japan
- Life Science Research Center; Nagano Children's Hospital; Azumino Japan
| | - E. Hidaka
- Department of Laboratory Medicine; Nagano Children's Hospital; Azumino Japan
- Life Science Research Center; Nagano Children's Hospital; Azumino Japan
| | - K. Sakashita
- Department of Hematology/Oncology; Nagano Children's Hospital; Azumino Japan
| | - S. Kojima
- Division of Blood Transfusion; Shinshu University Hospital; Matsumoto Japan
| | - S. Shimodaira
- Department of Regenerative Medicine; Kanazawa Medical University; Uchinada-Cho Kahoku-Gun Japan
| | - T. Nakamura
- Life Science Research Center; Nagano Children's Hospital; Azumino Japan
- Division of Neonatology; Nagano Children's Hospital; Azumino Japan
| |
Collapse
|
19
|
Saito A, Okiyama N, Kubota N, Fujimoto M. 666 Interferon-γ deficiency attenuates skin fibrosis in a murine model of chronic graft-versus-host disease-like scleroderma. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
20
|
Uehata Y, Yoshida M, Sato A, Fujimoto Y, Minematsu T, Sugama J, Sekine R, Kubota N, Sanada H. MON-LB325: A Change in Temporal Muscle Thickness Correlates with Past Energy Adequacy in Elderly Individuals: a Prospective Cohort Study. Clin Nutr 2017. [DOI: 10.1016/s0261-5614(17)31101-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
21
|
Testuz A, Nguyen V, Mathieu T, Kerneis C, Cimadevilla C, Kubota N, Codogno I, Tubiana S, Estrellat C, Vahanian A, Messika-Zeitoun D. P1644Influence of heart rate and systolic blood pressure on progression of calcific aortic valve stenosis - The COFRASA-GENERAC study. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1644] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- A. Testuz
- University Hospital of Geneva, Department of Cardiology, Geneva, Switzerland
| | - V. Nguyen
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - T. Mathieu
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - C. Kerneis
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - C. Cimadevilla
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - N. Kubota
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - I. Codogno
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - S. Tubiana
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - C. Estrellat
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - A. Vahanian
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | | | | |
Collapse
|
22
|
Han SH, Lee JH, Kim SY, Park KW, Chen C, Tripathi M, Dash A, Kubota N. Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer's disease. Acta Neurol Scand 2017; 135:252-256. [PMID: 26923256 DOI: 10.1111/ane.12571] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/28/2016] [Indexed: 12/01/2022]
Abstract
BACKGROUND Ethnic diversity between different populations may affect treatment safety and efficacy. AIMS AND METHODS A subanalysis to a global trial (study 326) was carried out to ascertain the safety and efficacy of donepezil 23 mg/day compared with donepezil 10 mg/day in Asian patients with moderate-to-severe Alzheimer's disease. Changes in cognition and global functioning were measured by the Severe Impairment Battery (SIB) and Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus), respectively, at week 24. RESULTS Cognitive improvement measured by SIB score was greater with donepezil 23 mg than with donepezil 10 mg (+1.36 vs -1.56]; difference, 2.92). There was no difference between the groups in global function measured by the CIBIC-Plus (3.94 and 3.95, respectively). Overall, 119 patients (82.1%) receiving donepezil 23 mg and 56 (71.8%) receiving donepezil 10 mg experienced ≥1 treatment emergent adverse events (TEAEs). In the donepezil 23 mg group, the incidence of TEAEs was higher among patients of lower weight (<55 kg) at baseline than in those of higher weight (64 of 75 patients [85.3%] vs 55 of 70 patients [78.5%]). CONCLUSIONS The benefits and risks associated with donepezil 23 mg in Asian patients are comparable to those of the global study population.
Collapse
Affiliation(s)
- S. -H. Han
- Department of Neurology; Konkuk University Hospital; Seoul South Korea
| | - J. -H. Lee
- Department of Neurology; University of Ulsan College of Medicine; Asan Medical Center; Seoul South Korea
| | - S. Y. Kim
- Department of Neurology; Clinical Neuroscience Center & Neurology; Seoul National University Bundang Hospita; Gyeonggi-do South Korea
| | - K. W. Park
- Department of Neurology; Dong-A University College of Medicine; Dong-A University Hospital; Busan South Korea
| | - C. Chen
- Department of Pharmacology; National University of Singapore and Memory Aging and Cognition Center; National University Health System; Singapore Singapore
| | - M. Tripathi
- Department of Neurology; Neuroscience Centre; AIIMS; New Delhi India
| | - A. Dash
- Regional Medical Advisor; Eisai Pharmaceuticals India Pvt. Ltd.; Mumbai India
| | - N. Kubota
- Clinical Development Eisai Co. Ltd.; Tokyo Japan
| |
Collapse
|
23
|
Testuz A, Kubota N, Nguyen V, Mathieu T, Kerneis C, Codogno I, Vahanian A, Messika-Zeitoun D. Influence of fetunin-A level on progression of calcific aortic valve stenosis – the COFRASA – GENERAC Study. Archives of Cardiovascular Diseases Supplements 2017. [DOI: 10.1016/s1878-6480(17)30197-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
24
|
Shimamura T, Hasegawa N, Kubota N. [Antifungal Activity of Luliconazole Nail Solution on in vitro and in vivo Onychomycosis Model]. Med Mycol J 2016; 57:J13-8. [PMID: 26936347 DOI: 10.3314/mmj.57.j13] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
We evaluated luliconazole nail solution, originally generated formulation, for the topical treatment of onychomycosis by two infection models. First, a suspension of Trichophyton mentagrophytes was dropped onto the ventral layer of human nail plate and these nails were set in Franz diffusion cells. After 9-day culture, luliconazole nail solutions (1, 3, and 5%) were applied to the dorsal surface of the nails once a day for 7 days. After application, fungal viability was assessed by measuring the ATP contents of the samples. The dose-dependent efficacy was confirmed, with 3% and 5% luliconazole nail solutions producing significantly lower ATP levels at 7-day treatment. When 3% and 5% luliconazole nail solutions were evaluated in a rabbit model of onychomycosis, both concentrations completely inhibited the recovery of fungi on culture after 4-week treatment. We therefore think these results indicate that 5% luliconazole nail solution is sufficiently potent for treatment of onychomycosis.
Collapse
|
25
|
Kubota N, David Messika-Zeitoun D. P650Influence of fetunin-a level on progression of calcific aortic valve stenosis The COFRASA - GENERAC Study. Eur Heart J Cardiovasc Imaging 2016; 17:ii130-ii136. [PMID: 28415102 DOI: 10.1093/ehjci/jew250.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Background. In recent years, pathophysiology of aortic stenosis (AS) has been considered as a possibly active inflammatory process, but its determinants remain unclear. Calcium tissue deposition observed in dilaysis patients have been linked to low level of Fetuin-A, a powerful inhibitor of ectopic calcification. It is thus suspected to play a role in development of aortic stenosis. Purpose. To assess correlation between Fetuin-A level and AS progression in a prospective cohort of AS patients, COFRASA (clinicalTrial.gov_number_NCT00338676) and GENERAC (clinicalTrial.gov_number_NCT00647088). Methods. A comprehensive clinical evaluation and Fetuin-A plasma level measurement was performed at baseline. AS severity was evaluated at baseline and yearly thereafter using echocardiography (mean pressure gradient (MPG)) and computed tomography (degree of aortic valve calcification or AVC). Annual progression was calculated as [(final measurement - baseline measurement)/follow-up duration] for both MPG and AVC measurements. Results. We enrolled 296 patients with at least 1 year of follow-up. Mean age was 74±10 years, 217 (73%) were men. Mean Fetuin-A level was 0.55±0.15 g/L. After a mean follow-up of 3.0±1.7 years, no correlation was found between AS progression and Fetuin-A level, using either MPG (r=0.015, p=0.82) or AVC (r=0.014, p=0.82). This was also true when comparing patients with lower level of Fetuin-A (≤0.53 g/L, the median in our cohort) with patients with higher level(+3±5 mmHg/year (median 2, [0-5] vs +4±4 mmHg/year (median 2, [1-6]) p=0.06, and +205±290 AUC/year (median 122, [32-269]) vs +240±310 AUC/year (median 145, [50-313], p=0.24). This was true also after adjustment for baseline severity and valve antomy. Conclusions. In our prospective cohortot of AS patients we found no impact of Fetuin-A on both hemodynamic and anatomic AS progression. Despite strong capacity to inhibit ectopic calcium deposition, Fetuin-A plasma level seems to have minor influence on AS progression.
Collapse
Affiliation(s)
- N Kubota
- Hospital Bichat-Claude Bernard, Service de Cardiologie, Paris, France
| | | |
Collapse
|
26
|
Ota T, Senaratne DNS, Preston NK, Ferrara F, Djikic D, Villemain O, Takahashi L, Niki K, Patrascu N, Benyounes N, Popa E, Diego Bellavia DB, Sundqvist M, Wei-Ting C, Papachristidis A, Djordjevic-Dikic A, Volpi C, Reis L, Nieto Tolosa J, Nishikawa H, D'angelo M, Testuz A, Mo YJ, Hashemi N, Toyota K, Nagamine K, Koide Y, Nomura T, Kurata J, Murakami Y, Kozuka Y, Ohshiro C, Thomas K, Townsend C, Wheeler S, Jacobson I, Elkington A, Balkhausen K, Bull S, Ring L, Gargani L, Carannante L, Russo V, D'alto M, Marra AM, Cittadini A, D'andrea A, Vriz O, Bossone E, Mujovic N, Dejanovic B, Peric V, Marinkovic M, Jankovic N, Orbovic B, Simic D, Sitefane F, Pernot M, Malekzadeh-Milani G, Baranger J, Bonnet D, Boudjemline Y, Uejima T, Nishikawa H, Semba H, Sawada H, Yamashita T, Sugawara M, Kayanuma H, Inoue K, Yagawa M, Takamisawa I, Umemura J, Yoshikawa T, Tomoike H, Mihalcea DJ, Mihaila S, Lungeanu L, Trasca LF, Bruja R, Neagu MS, Albu S, Cirstoiu M, Vinereanu D, Van Der Vynckt C, Gout O, Cohen A, Enache R, Jurcut R, Coman IM, Badea R, Platon P, Calin A, Beladan CC, Rosca M, Ginghina C, Popescu BA, Sonia Dell'oglio SD, Attilio Iacovoni AI, Calogero Falletta CF, Giuseppe Romano GR, Sergio Sciacca SS, Lissa Sugeng LS, Joseph Maalouf JM, Michele Pilato MP, Michele Senni MS, Cesare Scardulla CS, Francesco Clemenza FC, Salman K, Tornvall P, Ugander M, Chen ZC, Wang JJ, Fisch S, Liao RL, Roper D, Casar Demarco D, Papitsas M, Tsironis I, Byrne J, Alfakih K, Monaghan MJ, Boskovic N, Rakocevic I, Giga V, Tesic M, Stepanovic J, Nedeljkovic I, Aleksandric S, Kostic J, Beleslin B, Altman M, Annabi MS, Abouchakra L, Cucchini U, Muraru D, Badano LP, Ernande L, Derumeaux G, Teixeira R, Fernandes A, Almeida I, Dinis P, Madeira M, Ribeiro J, Puga L, Nascimento J, Goncalves L, Cambronero Sanchez FJ, Pinar Bermudez E, Gimeno Blanes JR, De La Morena Valenzuela G, Uejima T, Takahashi L, Semba H, Sawada H, Yamashita T, Lopez Fernandez T, Irazusta Cordoba FJ, Rosillo Rodriguez SO, Dominguez Melcon FJ, Meras Colunga P, Gemma D, Moreno Gomez R, Moreno Yanguela M, Lopez Sendon JL, Nguyen V, Mathieu T, Kerneis C, Cimadevilla C, Kubota N, Codogno I, Tubiana S, Estrellat C, Vahanian A, Messika-Zeitoun D, Ondrus T, Van Camp G, Di Gioia G, Barbato E, Bartunek J, Penicka M, Johnsson J, Gomez A, Alam M, Winter R. Poster Session 3The imaging examination and quality assessmentP626Value of mitral and tricuspid annular displacement to assess the interventricular systolic relationship in severe aortic valve stenosis : a Pilot studyP627Follow-up echocardiography in asymptomatic valve disease: assessing the potential economic impact of the European and American guidelines in a dedicated valve clinic, compared to standard care.P628The tricuspid valve: identification of optimal view for assessing for prolapseP629Right atrial volume by two-dimensional echocardiography in healthy subjectsP630Disturbance of inter and intra atrial conduction assessed by tissue doppler imaging in patients with medicaly controlled hypertension and prehypertension.P631Liver stiffness by shear wave elastography, new noninvasive and quantitative tool for acute variation estimation of central venous pressure in real-time?P632Weak atrial kick contribution is associated with a risk for heart failure decompensationP633Usefulness of wave intensity analysis in predicting the response to cardiac resynchronization therapyP634Early subclinical left ventricular systolic and diastolic dysfunction in gestational hypertension and preeclampsiaP635Clinical comparison of three different echocardiographic methods for left ventricular ejection fraction and LV end diastolic volume measurementP636Assessment of right ventricular-arterial coupling parameters by 3D echocardiography in patients with pulmonary hypertension receiving specific vasodilator therapyP637Prediction of right ventricular failure after left ventricular assist device implant: assessing usefulness of standard and strain echocardiographyP638Kinematic analysis of diastolic function using the novel freely available software Echo E-waves - feasibility and reproducibilityP639Evaluation of coronary flow velocity by Doppler echocardiography in the treatment of hypertension with the ARB: correlation to the histological cardiac fibrosisP640The clinical significance of limited apical ischaemia and the prognostic value of stress echocardiography - A contemporary study from a high volume centerP641Effects of intermediate stenosis of left anterior descending coronary artery on survival in patients with chronic total occlusion of right coronary arteryP642Left ventricular remodeling after a first myocardial infarction in patients with preserved ejection fraction at dischargeP643Left atrial size and acute coronary syndromes. Let is make simple.P644Influence of STEMI reperfusion strategy on systolic and diastolic functionP645Aortic valve resistance risk-stratifies low-gradient severe aortic stenosisP646Does permanent pacemaker implantation complicate the prognosis of patients after transcatheter aortic valve implantation?P647Influence of metabolic syndrome and diabetes on progression of calcific aortic valve stenosis - The COFRASA - GENERAC StudyP648Low referral for aortic valve replacement accounts for worse long-term outcome in low versus high gradient severe aortic stenosis with preserved ejection fractionP649The impact of right ventricular function from aortic valve replacement: A randomised study comparing minimally invasive aortic valve surgery and conventional open heart surgery. Eur Heart J Cardiovasc Imaging 2016. [DOI: 10.1093/ehjci/jew250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Abstract
PURPOSE To examine the enhancing effects of syringetin on the radiosensitivity of normal and cancer cells, and the related mechanism. MATERIALS AND METHODS We used normal human lung and mouse fibroblasts as well as human lung and mouse cancer cells derived from the above normal fibroblasts. Cell radiosensitivity was measured using a colony formation assay. Apoptosis was analyzed with DAPI staining and Western blots. DNA lesions were analyzed with γH2AX immunofluorescent staining. RESULTS The colony formation assay showed that syringetin enhanced radiosensitivity more effectively in cancer cells (H1299 and C3H/MCA clone 15) compared with normal cells (HFL-III and C3H/10T1/2). The radiosensitizing effect of syringetin was observed in mutated p53 and wild-type p53-transfected H1299 cells regardless of p53 status. Apoptosis was more frequently observed in X-ray-irradiated H1299 cells combined with syringetin compared with X-ray-only-treated cells. Enhanced apoptosis by syringetin was not observed in HFL-III cells. Western blot analysis showed that X-ray-induced Caspase-3 activation was enhanced by syringetin in H1299 cells. The number of X-ray-induced DNA double-strand breaks (DSB) measured by quantitative analysis of γH2AX foci was the same for H1299 cells treated with X-rays with or without syringetin. CONCLUSIONS This study supports the hypothesis that syringetin enhances radiosensitivity more effectively in cancer cells than in normal cells through enhancement of the Caspase-3-mediated apoptosis pathway. Syringetin could be useful in the development of novel efficacious radiosensitizers.
Collapse
Affiliation(s)
- Shin-Ichi Bando
- a Department of Biology , Center for Humanities and Sciences, Ibaraki Prefectural University of Health Sciences , Ibaraki , Japan
| | - Osamu Hatano
- b Department of Community Health and Epidemiology , Nara Medical University School of Medicine , Kashihara , Nara , Japan
| | - Hiroshi Takemori
- c Laboratory of Cell Signaling and Metabolic Disease , National Institutes of Biomedical Innovation , Ibaragi , Osaka , Japan
| | - Nobuo Kubota
- d Department of Radiological Sciences , Ibaraki Prefectural University of Health Sciences , Ibaraki , Japan
| | - Ken Ohnishi
- a Department of Biology , Center for Humanities and Sciences, Ibaraki Prefectural University of Health Sciences , Ibaraki , Japan
| |
Collapse
|
28
|
Shimamura T, Miyamae A, Imai A, Hirayanagi K, Iwanaga T, Kubota N, Shibuya K. Comparison of Characteristics of Two Topical Therapeutic Agents for Onychomycosis. Med Mycol J 2016; 57:J141-J147. [DOI: 10.3314/mmj.16-00020] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
| | | | - Ami Imai
- R&D Laboratories, POLA PHARMA INC
| | | | | | | | - Kazutoshi Shibuya
- Department of Surgical Pathology, Toho University School of Medicine
| |
Collapse
|
29
|
Shimamura T, Miyamae A, Arai M, Minemura A, Nozawa A, Kubota N. Distribution of Luliconazole in Nail Plate by In Vitro Permeation and Efficacy by Zone of Inhibition Test after Treatment of Luliconazole Nail Solution. Med Mycol J 2016; 57:J19-25. [DOI: 10.3314/mmj.57.j19] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
30
|
Kubota N, Nagasaka T, Umeda Y, Mori Y, Kimura K, Taniguchi F, Tanioka H, Fujiwara T, Goel A. Microrna-89 Expression As a Promising Prognostic Biomarker for Advanced Colorectal Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu326.51] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Kamijo K, Kurata N, Sarai A, Kubota N, Takei Y, Nanto H. CsBr:Eu Phosphor Ceramics as a New Photostimulable Phosphor Material for Two Dimensional X-ray Imaging Sensor. J NUCL SCI TECHNOL 2014. [DOI: 10.1080/00223131.2004.10875722] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
32
|
Amemiya S, Noji T, Kubota N, Nishijima T, Kita I. Noradrenergic modulation of vicarious trial-and-error behavior during a spatial decision-making task in rats. Neuroscience 2014; 265:291-301. [PMID: 24480363 DOI: 10.1016/j.neuroscience.2014.01.031] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2013] [Revised: 01/17/2014] [Accepted: 01/17/2014] [Indexed: 11/25/2022]
Abstract
Deliberation between possible options before making a decision is crucial to responding with an optimal choice. However, the neural mechanisms regulating this deliberative decision-making process are still unclear. Recent studies have proposed that the locus coeruleus-noradrenaline (LC-NA) system plays a role in attention, behavioral flexibility, and exploration, which contribute to the search for an optimal choice under uncertain situations. In the present study, we examined whether the LC-NA system relates to the deliberative process in a T-maze spatial decision-making task in rats. To quantify deliberation in rats, we recorded vicarious trial-and-error behavior (VTE), which is considered to reflect a deliberative process exploring optimal choices. In experiment 1, we manipulated the difficulty of choice by varying the amount of reward pellets between the two maze arms (0 vs. 4, 1 vs. 3, 2 vs. 2). A difficulty-dependent increase in VTE was accompanied by a reduction of choice bias toward the high reward arm and an increase in time required to select one of the two arms in the more difficult manipulation. In addition, the increase of c-Fos-positive NA neurons in the LC depended on the task difficulty and the amount of c-Fos expression in LC-NA neurons positively correlated with the occurrence of VTE. In experiment 2, we inhibited LC-NA activity by injection of clonidine, an agonist of the alpha2 autoreceptor, during a decision-making task (1 vs. 3). The clonidine injection suppressed occurrence of VTE in the early phase of the task and subsequently impaired a valuable choice later in the task. These results suggest that the LC-NA system regulates the deliberative process during decision-making.
Collapse
Affiliation(s)
- S Amemiya
- Department of Human Health Sciences, Tokyo Metropolitan University, Minamiohsawa, Hachioji, Tokyo 192-0397, Japan; Research Fellow of the Japan Society for the Promotion of Science, 5-3-1 Kojimachi, Chiyoda-ku, Tokyo 102-0083, Japan
| | - T Noji
- Department of Human Health Sciences, Tokyo Metropolitan University, Minamiohsawa, Hachioji, Tokyo 192-0397, Japan
| | - N Kubota
- Department of Human Health Sciences, Tokyo Metropolitan University, Minamiohsawa, Hachioji, Tokyo 192-0397, Japan
| | - T Nishijima
- Department of Human Health Sciences, Tokyo Metropolitan University, Minamiohsawa, Hachioji, Tokyo 192-0397, Japan
| | - I Kita
- Department of Human Health Sciences, Tokyo Metropolitan University, Minamiohsawa, Hachioji, Tokyo 192-0397, Japan.
| |
Collapse
|
33
|
Abstract
A new population balance model for solvent-mediated polymorphic transformation is presented.
Collapse
Affiliation(s)
- M. Kobari
- EN Technology Center
- JGC Corporation
- Yokohama, Japan
- Department of Applied Chemistry
- School of Science and Engineering
| | - N. Kubota
- Department of Chemistry and Bioengineering
- Iwate University
- Morioka, Japan
| | - I. Hirasawa
- Department of Applied Chemistry
- School of Science and Engineering
- Waseda University
- Tokyo, Japan
| |
Collapse
|
34
|
Segawa T, Fujii Y, Tanaka A, Bando SI, Okayasu R, Ohnishi K, Kubota N. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71. Int J Mol Med 2013; 33:559-64. [PMID: 24366006 DOI: 10.3892/ijmm.2013.1594] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2013] [Accepted: 12/13/2013] [Indexed: 11/05/2022] Open
Abstract
The molecular chaperone heat shock protein 90 (Hsp90) is involved in the maturation and stabilization of a wide range of oncogenic client proteins for oncogenesis and malignant cell proliferation, which renders this protein a promising target in the development of cancer therapeutics. PU-H71 is a purine-scaffold Hsp90 inhibitor with less toxicity in normal cells than in cancer cells. In this study, we examined the in vitro radiosensitizing activity and molecular mechanisms of action of PU-H71 in human lung cancer cell lines. PU-H71 enhanced the sensitivity of the SQ-5 and A549 cancer cells to radiation. When the cancer cells were pre-treated with PU-H71, the repair of DNA double-strand breaks (DSBs) was markedly inhibited after irradiation compared with the cells that were not pre-treated with PU-H71, as evaluated by counting the foci of phosphorylated histone H2AX (γ-H2AX). We further demonstrated that post-irradiation, PU-H71 inhibited Rad51 foci formation, a critical protein for the homologous recombination pathway of DNA DSB repair. These data indicate that targeting Hsp90 with PU-H71 may be novel therapeutic strategy for radioresistant carcinomas.
Collapse
Affiliation(s)
- Tatsuya Segawa
- Department of Radiological Sciences, Center for Humanity and Arts, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394, Japan
| | - Yoshihiro Fujii
- Department of Radiological Sciences, Center for Humanity and Arts, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394, Japan
| | - Aya Tanaka
- Department of Radiological Sciences, Center for Humanity and Arts, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394, Japan
| | - Shin-Ichi Bando
- Department of Biology, Center for Humanity and Arts, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394, Japan
| | - Ryuichi Okayasu
- Heavy-ion Radiobiology Group, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Inage-ku, Chiba 263-8555, Japan
| | - Ken Ohnishi
- Department of Biology, Center for Humanity and Arts, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394, Japan
| | - Nobuo Kubota
- Department of Radiological Sciences, Center for Humanity and Arts, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394, Japan
| |
Collapse
|
35
|
Fujii Y, Yurkon CR, Maeda J, Genet SC, Kubota N, Fujimori A, Mori T, Maruo K, Kato TA. Comparative study of radioresistance between feline cells and human cells. Radiat Res 2013; 180:70-7. [PMID: 23772923 DOI: 10.1667/rr3194.1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Radioresistance of cats has been seen in animal radiotherapy. Feline radioresistance and its underlying mechanism(s) were investigated in fibroblast cells and lymphocytes. We hypothesized that radioresistance was attributable to an increase in the cells ability to repair DNA damage. To investigate this hypothesis, fibroblast cells were exposed to various doses of X rays and then colony formation assays were performed. Survival curves showed that potential lethal damage repair (PLDR) for feline cells were greater than that for human cells. γ-H2AX foci assays were performed to evaluate DNA double-strand breaks (DSBs) formation and repair kinetics. After PLDR, feline cells displayed a decreased residual amount of γ-H2AX foci. Formation of chromosome aberrations (dicentrics) after PLDR as an indicator of radiation-induced DNA damage and repair; human, feline and canine lymphocytes were evaluated. Human and canine lymphocytes showed two to three times the number of dicentrics compared to feline lymphocytes. Finally, micronuclei assays were performed to further confirm the radioresistant nature of feline lymphocytes. In concordance with the results of the chromosome aberration assay, the number of micronuclei in feline lymphocytes was less than observed in human and canine lymphocytes. Taken together, these results show that DNA and chromosome damage induced by X irradiation is more effectively repaired in feline cells, resulting in less residual damage. Our results suggest that both feline fibroblasts and lymphocytes are more radioresistant compared to human cells of similar tissues, and this resistance can be contributed, at least in part, to greater ability for PLDR.
Collapse
Affiliation(s)
- Yoshihiro Fujii
- Department of Radiological Sciences, Ibaraki Prefectural University of Health Sciences, 4669-2 Ami, Inashiki, Ibaraki, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Fujii Y, Genet MD, Roybal EJ, Kubota N, Okayasu R, Miyagawa K, Fujimori A, Kato TA. Comparison of the bromodeoxyuridine-mediated sensitization effects between low-LET and high-LET ionizing radiation on DNA double-strand breaks. Oncol Rep 2013; 29:2133-9. [PMID: 23525528 DOI: 10.3892/or.2013.2354] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2012] [Accepted: 12/17/2012] [Indexed: 11/06/2022] Open
Abstract
The incorporation of halogenated pyrmidines such as bromo- and iodo-deoxyuridines (BrdU, IdU) into DNA as thymidine analogs enhances cellular radiosensitivity when high-linear energy transfer (LET) radiation is not used. Although it is known that high-LET ionizing radiation confers fewer biological effects resulting from halogenated pyrimidine incorporation, the exact mechanisms of reduced radiosensitivity with high-LET radiation are not clear. We investigated the radiosensitization effects of halogenated pyrimidines with high-LET radiation using accelerated carbon and iron ions. Cells synchronized into the G1 phase after unifilar (1 cell cycle) and bifilar (2 cell cycles) substitution with 10 µM BrdU were exposed to various degrees of LET with heavy ions and X-rays. We then carried out a colony formation assay to measure cell survival. The γ-H2AX focus formation assay provided a measure of DNA double-strand break (DSB) formation and repair kinetics. Chromosomal aberration formations for the first post-irradiation metaphase were also scored. For both low-LET X-rays and carbon ions (13 keV/µm), BrdU incorporation led to impaired DNA repair kinetics, a larger initial number of DNA DSBs more frequent chromosomal aberrations at the first post-irradiated metaphase, and increased radiosensitivity for cell lethality. The enhancement ratio was higher after bifilar substitution. In contrast, no such synergistic enhancements were observed after high-LET irradiation with carbon and iron ions (70 and 200 keV/µm, respectively), even after bifilar substitution. Our results suggest that BrdU substitution did not modify the number and quality of DNA DSBs produced by high-LET radiation. The incorporation of halogenated pyrimidines may produce more complex/clustered DNA damage along with radicals formed by low-LET ionizing radiation. In contrast, the severity of damage produced by high-LET radiation may undermine the effects of BrdU and account for the observed minimal radiosensitization effects.
Collapse
Affiliation(s)
- Yoshihiro Fujii
- Department of Radiological Sciences, Ibaraki Prefectural University of Health Sciences, Inashiki, Ibaraki 300-0394, Japan
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Yasui H, Asanuma T, Kino J, Yamamori T, Meike S, Nagane M, Kubota N, Kuwabara M, Inanami O. The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption. BMC Cancer 2013; 13:106. [PMID: 23496909 PMCID: PMC3599813 DOI: 10.1186/1471-2407-13-106] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2012] [Accepted: 03/03/2013] [Indexed: 11/24/2022] Open
Abstract
Background Glioblastoma is one of the intractable cancers and is highly resistant to ionizing radiation. This radioresistance is partly due to the presence of a hypoxic region which is widely found in advanced malignant gliomas. In the present study, we evaluated the effectiveness of the hypoxic cell sensitizer doranidazole (PR-350) using the C6 rat glioblastoma model, focusing on the status of blood brain barrier (BBB). Methods Reproductive cell death in the rat C6 glioma cell line was determined by means of clonogenic assay. An intracranial C6 glioma model was established for the in vivo experiments. To investigate the status of the BBB in C6 glioma bearing brain, we performed the Evans blue extravasation test. Autoradiography with [14C]-doranidazole was performed to examine the distribution of doranidazole in the glioma tumor. T2-weighted MRI was employed to examine the effects of X-irradiation and/or doranidazole on tumor growth. Results Doranidazole significantly enhanced radiation-induced reproductive cell death in vitro under hypoxia, but not under normoxia. The BBB in C6-bearing brain was completely disrupted and [14C]-doranidazole specifically penetrated the tumor regions. Combined treatment with X-irradiation and doranidazole significantly inhibited the growth of C6 gliomas. Conclusions Our results revealed that BBB disruption in glioma enables BBB-impermeable radiosensitizers to penetrate and distribute in the target region. This study is the first to propose that in malignant glioma the administration of hydrophilic hypoxic radiosensitizers could be a potent strategy for improving the clinical outcome of radiotherapy without side effects.
Collapse
Affiliation(s)
- Hironobu Yasui
- Laboratory of Radiation Biology, Department of Environmental Veterinary Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Kita 18 Nishi 9, Kita-ku, Sapporo, Hokkaido, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Kobari M, Kubota N, Hirasawa I. Deducing primary nucleation parameters from metastable zone width and induction time data determined with simulation. CrystEngComm 2013. [DOI: 10.1039/c2ce26679b] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
39
|
Nakamura A, Tajima K, Zolzaya K, Sato K, Inoue R, Yoneda M, Fujita K, Nozaki Y, Kubota KC, Haga H, Kubota N, Nagashima Y, Nakajima A, Maeda S, Kadowaki T, Terauchi Y. Protection from non-alcoholic steatohepatitis and liver tumourigenesis in high fat-fed insulin receptor substrate-1-knockout mice despite insulin resistance. Diabetologia 2012; 55:3382-91. [PMID: 22955994 DOI: 10.1007/s00125-012-2703-1] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2012] [Accepted: 07/27/2012] [Indexed: 12/20/2022]
Abstract
AIMS/HYPOTHESIS Epidemiological studies have revealed that obesity and diabetes mellitus are independent risk factors for the development of non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. However, the debate continues on whether insulin resistance as such is directly associated with NASH and liver tumourigenesis. Here, we investigated the incidence of NASH and liver tumourigenesis in Irs1 ( -/- ) mice subjected to a long-term high-fat (HF) diet. Our hypothesis was that hepatic steatosis, rather than insulin resistance may be related to the pathophysiology of these conditions. METHODS Mice (8 weeks old, C57Bl/6J) were given free access to standard chow (SC) or an HF diet. The development of NASH and liver tumourigenesis was evaluated after mice had been on the above-mentioned diets for 60 weeks. Similarly, Irs1 ( -/- ) mice were also subjected to an HF diet for 60 weeks. RESULTS Long-term HF diet loading, which causes obesity and insulin resistance, was sufficient to induce NASH and liver tumourigenesis in the C57Bl/6J mice. Obesity and insulin resistance were reduced by switching mice from the HF diet to SC, which also protected these mice against the development of NASH and liver tumourigenesis. However, compared with wild-type mice fed the HF diet, Irs1 ( -/- ) mice fed the HF diet were dramatically protected against NASH and liver tumourigenesis despite the presence of severe insulin resistance and marked postprandial hyperglycaemia. CONCLUSIONS/INTERPRETATION IRS-1 inhibition might protect against HF diet-induced NASH and liver tumourigenesis, despite the presence of insulin resistance.
Collapse
Affiliation(s)
- A Nakamura
- Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Shojima N, Hara K, Fujita H, Horikoshi M, Takahashi N, Takamoto I, Ohsugi M, Aburatani H, Noda M, Kubota N, Yamauchi T, Ueki K, Kadowaki T. Depletion of homeodomain-interacting protein kinase 3 impairs insulin secretion and glucose tolerance in mice. Diabetologia 2012; 55:3318-30. [PMID: 22983607 DOI: 10.1007/s00125-012-2711-1] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/05/2012] [Accepted: 08/07/2012] [Indexed: 01/13/2023]
Abstract
AIMS/HYPOTHESIS Insufficient insulin secretion and reduced pancreatic beta cell mass are hallmarks of type 2 diabetes. Here, we focused on a family of serine-threonine kinases known as homeodomain-interacting protein kinases (HIPKs). HIPKs are implicated in the modulation of Wnt signalling, which plays a crucial role in transcriptional activity, and in pancreas development and maintenance. The aim of the present study was to characterise the role of HIPKs in glucose metabolism. METHODS We used RNA interference to characterise the role of HIPKs in regulating insulin secretion and transcription activity. We conducted RT-PCR and western blot analyses to analyse the expression and abundance of HIPK genes and proteins in the islets of high-fat diet-fed mice. Glucose-induced insulin secretion and beta cell proliferation were measured in islets from Hipk3 ( -/- ) mice, which have impaired glucose tolerance owing to an insulin secretion deficiency. The abundance of pancreatic duodenal homeobox (PDX)-1 and glycogen synthase kinase (GSK)-3β phosphorylation in Hipk3 ( -/- ) islets was determined by immunohistology and western blot analyses. RESULTS We found that HIPKs regulate insulin secretion and transcription activity. Hipk3 expression was most significantly increased in the islets of high-fat diet-fed mice. Furthermore, glucose-induced insulin secretion and beta cell proliferation were decreased in the islets of Hipk3 ( -/- ) mice. Levels of PDX1 and GSK-3β phosphorylation were significantly decreased in Hipk3 ( -/- ) islets. CONCLUSIONS/INTERPRETATION Depletion of HIPK3 impairs insulin secretion and glucose tolerance. Decreased levels of HIPK3 may play a substantial role in the pathogenesis of type 2 diabetes.
Collapse
Affiliation(s)
- N Shojima
- Department of Diabetes and Metabolic Disease, Graduate School of Medicine, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Takeda Y, Kubota N, Nishio K, Funayama Y, Gemma A, Niitani H, Saijo N. Cross-resistance to antineoplastic agents in a human small-cell lung-cancer subline resistant to okadaic Acid. Oncol Rep 2012; 2:705-10. [PMID: 21597801 DOI: 10.3892/or.2.5.705] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
We report on a human small cell lung cancer subline (H69/OA100) resistant to okadaic acid, an inhibitor of protein phosphatases. H69/OA100 showed cross-resistance to cis-diamminedichloroplatinum(II) (CDDP), adriamycin, and vinca alkaloids. Intracellular retention of adriamycin and CDDP in H69/OA100 was the same as those in H69. H69/OA100 was not shown to express MDR-1 by the reverse transcription polymerase chain reaction method. Expression level of mRNA of multidrug resistance-associated protein (MRP) in H69/OA100 was the same as that in H69. These data suggest that the mechanism of drug resistance in H69/OA100 might be due to a new mechanism of non-P-glycoprotein mediated multidrug resistance.
Collapse
Affiliation(s)
- Y Takeda
- NATL CANC CTR,RES INST,DIV PHARMACOL,CHUO KU,TOKYO 104,JAPAN. NIPPON MED COLL,DEPT INTERNAL MED 4,BUNKYO KU,TOKYO 104,JAPAN
| | | | | | | | | | | | | |
Collapse
|
42
|
Kuzumoto K, Kubota N, Ishii K, Yumoto K, Ogiso Y, Nakamura T, Katsuyama T, Oana K, Kawakami Y. Successful cessation of transmitting healthcare -- associated infections due to Burkholderia cepacia complex in a neonatal intensive care unit in a Japanese children's hospital. Eur J Med Res 2012; 16:537-42. [PMID: 22112360 PMCID: PMC3351897 DOI: 10.1186/2047-783x-16-12-537] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Background Burkholderia cepacia strains have been known to possess the capability to cause serious infections especially in neonatal intensive care units (NICUs), and their multi-drug resistances become a severe threat in hospital settings. The aim of this investigation was to evaluate the B. cepacia complex infections in the NICU in Nagano Children's Hospital, Azumino 399-8288, Japan, and to report the intervention leading to the successful cessation of the outbreak. Methodology The incidence of isolation and antimicrobial susceptibilities of nosocomial Burkholderia cepacia complex strains during a four-year period were retrospectively examined by clinical microbiological records, and by pulsed-field gel electrophoresis analyses along with the bacteriological verification of disinfectant device itself and procedures for its maintenance routinely used in the NICU. Results During the period surveyed between 2007 and 2009, only an isolate per respective year of B. cepacia complex was recovered from each neonate in the NICU. However, in 2010, the successive 6 B. cepacia complex isolates were recovered from different hospitalized neonates. Among them, an isolate was originated from peripheral blood of a neonate, apparently giving rise to systemic infection. In addition, the hospitalized neonate with bacteremia due to B. cepacia complex also exhibited positive cultures from repeated catheterized urine samples together with tracheal aspirate secretions. However other 5 isolates were considered as the transients or contaminants having little to do with infections. Moreover, the 5 isolates between July and October in 2010 revealed completely the same electrophoresis patterns by means of pulsed-field gel electrophoresis analyses, strongly indicating that they were infected through the same medical practices, or by transmission of the same contaminant. Conclusions A small outbreak due to B. cepacia complex was brought about in the NICU in 2010, which appeared to be associated with the same genomovar of B. cepacia complex. The source or the rout of infection was unknown in spite of the repeated epidemiological investigation. It is noteworthy that no outbreak due to B. cepacia complex was noted in the NICU after extensive surveillance intervention.
Collapse
Affiliation(s)
- K Kuzumoto
- Department of Laboratory Medicine, Nagano Children's Hospital, Azumino, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Nakamura A, Togashi Y, Orime K, Sato K, Shirakawa J, Ohsugi M, Kubota N, Kadowaki T, Terauchi Y. Control of beta cell function and proliferation in mice stimulated by small-molecule glucokinase activator under various conditions. Diabetologia 2012; 55:1745-54. [PMID: 22456697 DOI: 10.1007/s00125-012-2521-5] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2011] [Accepted: 02/20/2012] [Indexed: 12/15/2022]
Abstract
AIMS/HYPOTHESIS We investigated changes in the expression of genes involved in beta cell function and proliferation in mouse islets stimulated with glucokinase activator (GKA) in order to elucidate the mechanisms by which GKA stimulates beta cell function and proliferation. METHODS Islets isolated from mice were used to investigate changes in the expression of genes related to beta cell function and proliferation stimulated by GKA. In addition, Irs2 knockout (Irs2 (-/-)) mice on a high-fat diet or a high-fat diet containing GKA were used to investigate the effects of GKA on beta cell proliferation in vivo. RESULTS In wild-type mice, Irs2 and Pdx1 expression was increased by GKA. In Irs2 (-/-) mice, GKA administration increased the glucose-stimulated secretion of insulin and Pdx1 expression, but not beta cell proliferation. It was particularly noteworthy that oxidative stress inhibited the upregulation of the Irs2 and Pdx1 genes induced by GKA. Moreover, whereas neither GKA alone nor exendin-4 alone upregulated the expression of Irs2 and Pdx1 in the islets of db/db mice, prior administration of exendin-4 to the mice caused GKA to increase the expression of these genes. CONCLUSIONS/INTERPRETATION GKA-stimulated IRS2 production affected beta cell proliferation but not beta cell function. Oxidative stress diminished the effects of GKA on the changes in expression of genes involved in beta cell function and proliferation. A combination of GKA and an incretin-related agent might therefore be effective in therapy.
Collapse
Affiliation(s)
- A Nakamura
- Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Kobari M, Kubota N, Hirasawa I. Secondary nucleation-mediated effects of stirrer speed and growth rate on induction time for unseeded solution. CrystEngComm 2012. [DOI: 10.1039/c2ce25248a] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
45
|
Nishimura Y, Hattori M, Ohbu M, Kobayashi M, Konishi H, Miyazaki H, Kubota E, Kubota N. Utility of intraoral washing cytology as a diagnostic technique in maxillary sinus carcinoma with oral invasion. Cytopathology 2011; 24:67-9. [PMID: 22023705 DOI: 10.1111/j.1365-2303.2011.00933.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
46
|
Ohara M, Kimura S, Tanaka A, Ohnishi K, Okayasu R, Kubota N. Benzyl isothiocyanate sensitizes human pancreatic cancer cells to radiation by inducing apoptosis. Int J Mol Med 2011; 28:1043-7. [PMID: 21833466 DOI: 10.3892/ijmm.2011.770] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2011] [Accepted: 07/27/2011] [Indexed: 11/06/2022] Open
Abstract
Isothiocyanates are a class of naturally occurring chemopreventive agents known to suppress proliferation of cancer cells in culture. The present study was undertaken in order to examine the effects of benzyl isothiocyanate (BITC), one of the common dietary isothiocyanates, on the radiosensitivity of human pancreatic cancer cells and to gain insights into the underlying molecular mechanism of BITC-induced radiosensitization. Two human pancreatic cancer cell lines, PANC-1 and MIAPaCa-2, were treated with BITC and irradiated with X-rays. Radiation sensitivity, apoptosis, and protein levels were determined by a clonogenic assay, fluorescence microscopic analysis with DAPI staining and Western blotting, respectively. MIAPaCa-2 cells were relatively more sensitive to BITC treatment compared with PANC-1 cells. Radiosensitization was observed in both PANC-1 and MIAPaCa-2 cells incubated with BITC at 5 to 10 µM and 2.5 to 5 µM for 24 h, respectively. The combination treatments with BITC and X-rays also revealed an increased percentage of apoptotic cells. In addition, treatment with BITC and X-rays resulted in a decrease in the protein levels of the X-linked inhibitor of apoptosis (XIAP), inhibitor of apoptosis (IAP) family protein, and in a marked increase in the apoptosis protease activating factor-1 (Apaf-1), essential for activation of caspase-9 in stress-induced apoptosis. BITC may be a useful radiosensitizer for radiotherapy of pancreatic cancers.
Collapse
Affiliation(s)
- Maki Ohara
- Department of Radiological Sciences, Center for Humanity and Sciences, Ibaraki Prefectural University of Health Sciences, Ami, Inashiki-gun, Ibaraki 300-0394, Japan
| | | | | | | | | | | |
Collapse
|
47
|
Hayakawa M, Sawamura A, Sugano M, Uegaki S, Kubota N, Gando S, Jesmin S. Thrombin-activatable fibrinolysis inhibitor and organ dysfunction in disseminated intravascular coagulation associated with sepsis. Crit Care 2011. [PMCID: PMC3239244 DOI: 10.1186/cc10370] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
48
|
Kwong W, Neilson AL, Hamilton RM, Chiu CC, Stephenson EA, Gross GJ, Soucie L, Kirsh JA, xian-hui Z, Bao-peng T, Jin-xin L, Yu Z, Yan-yi Z, Jiang-hua Z, Hirahara T, Sugawara Y, Suga C, Ako J, Momomura S, Ardashev AV, Zhelyakov EG, Konev AV, Rybachenko MS, Belenkov YN, Bai R, Di Biase L, Santangeli P, Saenz LC, Verma A, Sanchez J, Tondo C, Natale A, Safari F, Hajizadeh S, Mani A, Khoshbaten A, Foadoddini M, Forush SS, Bayat G, Kim SH, Chong D, Ching CK, Liew R, Galalardin, Khin MW, Teo WS, Chong D, Tan BY, Liew R, Ching CK, Teo WS, Sakamoto T, Al Mehairi M, Al Ghamdi SA, Dagriri K, Al Fagih A, Selvaraj R, Ezhumalai B, Satheesh S, Ajit A, Gobu P, Balachander J, Liu XQ, Zhou X, Yang G, Zhong GZ, Shi L, Tian Y, Li YB, Wang AH, Yang XC, Takenaka S, Ozaki H, Nakamura M, Otsuka M, Tsurumi Y, Nolker G, Gutleben KJ, Ritscher G, Sinha AM, Muntean B, Heintze J, Vogt J, Brachmann J, Horstkotte D, Katsuyuki T, Katsuyuki T, McGrew F, Johnson E, Coppess M, Fan I, Li S, Zhiyu L, Zengzhang L, Xianbin L, Yuehui Y, Min L, Shu-long Z, Dong C, Zhi-tao Z, Xian-jing W, Ying-xue D, Shu-Long Z, Dong C, Zhi-Tao Z, Xian-Jing W, Ying-Xue D, Liu P, Guo JH, Zhang Z, Li J, Liu HG, Zhang HC, Zvereva V, Rillig A, Meyerfeldt U, Jung W, Wei L, Qi G, Zhang Q, Xia Y, Doi A, Satomi K, Nakajima I, Makimoto H, Yokoyama T, Yamada Y, Okamura H, Noda T, Aiba T, Shimizu W, Aihara N, Kamakura S, Li Z, Zhao QY, Huang CX, Doi A, Satomi K, Nakajima I, Makimoto H, Yokoyama T, Yamada Y, Okamura H, Noda T, Aiba T, Shimizu W, Aihara N, Kamakura S, Min-Seok C, Jeong-Wook P, Young-Woong H, Sung-Eun P, Jae-Sun U, Yong-Seog O, Woo-Seung S, Ji-Hoon K, Seong-Won J, Man-Young L, Tae-Ho R, Uhm JS, Oh YS, Choi MS, Park JW, Ha YW, Park SE, Jang SW, Shin WS, Kim JH, Lee MY, Rho TH, Nielsen JB, Olesen MS, Tango M, Haunso S, Holst AG, Svendsen JH, Poci D, Thogersen AM, Riahi S, Linde P, Edvardsson N, Khoo CW, Krishnamoorthy S, Dwivedi G, Balakrishnan B, Lim HS, Lip GYH, Khoo CW, Krishnamoorthy S, Dwivedi G, Balakrishnan B, Lim HS, Lip GYH, D'Ascia S, D'ascia C, Marino V, Chiariello M, Santulli G, Music L, Anderson K, Benzaquen BS, Saponieri C, Yassin H, Fridman V, Vasavada BC, Turitto G, El-Sherif N, Saponieri C, Prabhu H, Yassin H, Fridman V, Huang Y, Vasavada BC, Turitto G, El-Sherif N, Ortega MC, Sosa ESH, Ugalde AN, Al Jamil A, Abu Siddique M, Haque KMHSS, Suga C, Hirahara T, Sugawara Y, Ako J, Momomura SI, Mlynarski R, Mlynarska A, Ilczuk G, Mlynarski R, Mlynarska A, Wilczek J, Mlynarska A, Mlynarski R, Wilczek J, Mlynarska A, Mlynarski R, Wilczek J, Sosnowski M, Kohno R, Abe H, Nagatomo T, Oginosawa Y, Minamiguchi H, Otsuji Y, Kohno R, Abe H, Minamiguchi H, Oginosawa Y, Nagatomo T, Otsuji Y, Minamiguchi H, Abe H, Kohno R, Oginosawa Y, Otsuji Y, Ekinci S, Yesil M, Bayata S, Vurgun VK, Arikan E, Postaci N, Xiaoqing R, Jielin P, Shu Z, Liang M, Fangzheng W, Takahashi K, Tokano T, Nakazato Y, Doi S, Shiozawa T, Konishi H, Hiki M, Kato Y, Komatsu S, Takahashi S, Kubota N, Tamura H, Suwa S, Ohki M, Katsumata T, Kizu K, Bito F, Sumiyoshi M, Juntendo HD, Yamada Y, Okamura H, Nakajima I, Doi A, Makimoto H, Yukoyama T, Noda T, Satomi K, Aiba T, Shimizu W, Aihara N, Kamakura S, Perna F, Leo M, Leccisotti L, Casella M, Pelargonio G, Lago M, Bencardino G, Narducci ML, Russo E, Santangeli P, Giordano A, Bellocci F, Song T, Yang J, Huang C, Zhang J, Huang C, Wu P, Yang J, Song T, Chen Y, Fan X, Wang T, Wang X, Tang Y, Wu P, Huang CX, Zhang J, Fan XR, Chen YJ, Li XW, Yang J, Song T, Chiu CC, Buescher T, Obias-Manno D, Yoo CJ, Huh J, Ortega MC, Nakanishi H, Hirata A, Wada M, Kashiwase K, Okada M, Ueda Y, Su D, Niu XL, Song AQ, Kohno R, Abe H, Minamiguchi H, Oginosawa Y, Nagatomo T, Otsuji Y, Fujii S, Yambe Y, Shiiba K, Sakakibara M, Takenaka S, Watanabe A, Wada T, Koide Y, Ikeda M, Toda H, Hashimoto K, Terasaka R, Nakahama M, Wada T, Watanabe A, Koide Y, Ikeda M, Toda H, Hashimoto K, Terasaka R, Nakahama M, Okada Y, Mizuno H, Ide H, Ueno T, Kogaki S, Ozono K, Nanto S, Statescu C, Bercea R, Sascau RA, Georgescu CA, Ortega MC, Athanas E, Ortega MC, Athanas E, Mironov NY, Bakalov SA, Jarova EA, Rodionova ES, Mironova NA, Kim J, Ahn MS, Han DC, Choo JTL, Chen CK, Tan TH, Ong KK, Kam R, Curnis A, Bontempi L, Coppola G, Cerini M, Vassanelli F, Lipari A, Gennaro F, Pagnoni C, Ashofair N, Cas LD, Gourineni V, Wong KL, Davoudi R, Hamid N, Chong D, Yew TB, Liew R, Keong CC, Siong TW, Fuke E, Shimizu H, Kimura S, Hao K, Watanabe R, Seo JB, Chung WY, Kim SH, Kim MA, Zo ZH, Krishinan S, Skuratova NA, Belyaeva LM, Bae MH, Lee JH, Lee HS, Yang DH, Park HS, Cho Y, Chae SC, Jun JE, Rychkova LV, Dolgikh VV, Zurbanova LV, Zurbanov AV, Aleksanyan A, Matevosyan A, Podosyan G, Zelveian P, Aleksanyan A, Podosyan G, Matevosyan A, Zelveian P, Choi HO, Nam GB, Kim YR, Kim KH, Kim SH, Choi KJ, Kim YH, Pakpahan HAP, Wei D, Qizhu T, Xiaofei Y, Kai G, Siting F, Ji H, Sato A, Tanabe Y, Hayashi Y, Yoshida T, Ito E, Chinushi M, Hasegawa K, Yagihara N, Iijima K, Izumi D, Watanabe H, Furushima H, Aizawa Y, Dong YX, Dong YX, Burnett JC, Chen HH, Sandberg S, Zhang Y, Chen PS, Cha YM, Mlynarski R, Mlynarska A, Wilczek J, Sosnowski M, Zhou XH, Tang BP, Li JX, Zhang Y, Li YD, Zhang JH, Arsenos P, Gatzoulis K, Gialernios T, Dilaveris P, Sideris S, Archontakis S, Tsiachris D, Christodoulos S, Feng Z, Baogui S, Li L, Ming L, Bai R, Di Biase L, Mohanty P, Hesselson AB, De Ruvo E, Gallagher PL, Minati M, Natale LCA, Tomassoni GF, Gan T, Tang B, Xu G, Li J, Zhang Y, Zhou X, Zhang Y, Hosoda J, Ishikawa T, Matsushita K, Matsumoto K, Kimura Y, Miyamoto M, Sugano T, Ishigami T, Uchino K, Kimura K, Umemura S, Nakajima I, Noda T, Shimizu W, Yokoyama T, Makimoto H, Doi A, Yamada Y, Okamura H, Satomi K, Aiba T, Aihara N, Kamakura S, Nakajima I, Noda T, Shimizu W, Kurita T, Yokoyama T, Makimoto H, Doi A, Yamada Y, Okamura H, Satomi K, Aiba T, Aihara N, Kamakura S, Wang T, Huang CX, Wang T, Huang CX, Ruan L, Zhang C, Cai S, Bai R, Liu N, Ruan Y, Quan X, Kang JK, Kim NY, Park SH, Lee JH, Park HS, Cho Y, Chae SC, Jun JE, Park WH, Sapelnikov OV, Latypov RS, Grishin IR, Mareev YV, Saidova MA, Akchurin RS, Arsenos P, Gatzoulis K, Manis G, Dilaveris P, Archontakis S, Tsiachris D, Mytas D, Papafanis T, Papavasileiou MV, Stefanadis C, Ren LN, Fang XH, Wang YQ, Qi GX, Zeng QX, Zheng ZT, Zhong JQ, Wang YL, Liu HZ, Liu DL, Meng XL, Li JS, Zhang Y, Liu HZ, Zhong JQ, Zeng QX, Liu DL, Meng XL, Li JS, Su GY, Wang J, Zhang Y, Liu HZ, Zhong JQ, Zeng QX, Wang YL, Liu DL, Meng XL, Li JS, Su GY, Zhang Y, Li JS, Zhong JQ, Zeng QX, Liu HZ, Su GY, Zhang Y, Li JS, Zhong JQ, Zeng QX, Liu HZ, Meng XL, Liu DL, Su GY, Zhang Y, Li JS, Zhong JQ, Zeng QX, Liu HZ, Meng XL, Liu DL, Su GY, Zhang Y, Nicolson WB, Kundu S, Tyagi N, Meatcher PDS, Yusuf S, Jeilan M, Stafford PJ, Sandilands AJ, Loke I, Ng GA, Nicolson WB, Kundu S, Tyagi N, Meatcher PDS, Yusuf S, Jeilan M, Stafford PJ, Sandilands AJ, Loke I, Ng GA, Solak Y, Gul EE, Atalay H, Abdulhalikov T, Kayrak M, Turk S, Kang JK, Kim NY, Park SH, Lee JH, Park HS, Cho Y, Chae SC, Jun JE, Park WH, Belyaeva LM, Skuratova NA, Pogodina AV, Dolgikh VV, Valjavskaja OV, Zurbanov AV, Chen YX, Luo NS, Wang JF, Zhang S, Ishimaru S, Miyakawa M, Kakinoki R, Tadokoro M, Kitani S, Sugaya T, Nishimura K, Igarashi T, Okabayashi H, Furuya J, Igarashi Y, Igarashi K, Su T, Winlaw D, Chard R, Nicholson I, Sholler G, Lau K, Sun Q, Cheng KP, Cheng R, Hua W, Pu JL, Zhang S, Lim CP, Chan LL, Teo LW, Kwok BWK, Sim DKL, Ching CK, Lim CP, Chan LL, Teo LW, Kwok BWK, Sim DKL, Ching CK, Curnis A, Bontempi L, Cerini M, Lipari A, Vassanelli F, Pagnoni C, Ashofair N, Moneghini D, Cestari R, Cas LD, Al Fagih A, Al Shurafa H, Al Ghamdi S, Dagriri K, Al Khadra A, Iijima K, Chinushi M, Hasegawa K, Yagihara N, Sato A, Izumi D, Watanabe H, Furushima H, Aizawa Y, Furushima H, Chinushi M, Iijima K, Izumi D, Hasegawa K, Yagihara N, Watanabe H, Sato A, Aizawa Y, Agacdiken A, Yalug I, Vural A, Celikyurt U, Ural D, Aker T, Agacdiken A, Yalug I, Vural A, Celikyurt U, Ural D, Aker T, Heintze J, Schloss E, Auricchio A, Zeng C, Sterns L, Farooqi F, Kamdar R, Adhya S, Bayne S, Jackson T, Pollock L, Sterns L, Gall N, Murgatroyd F, Guo Y, Wang Y, Yang T, Zhu P, Liu H, Zhao Y, Zhang L, Gao W, Gao M. Poster presentation. Europace 2011. [DOI: 10.1093/europace/euq492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
49
|
Kubota N, Hayashi S. Development of resonance-enhanced multiphoton ionization SNMS for state-selective detection of sputtered atoms under low-energy ion irradiation. SURF INTERFACE ANAL 2011. [DOI: 10.1002/sia.3732] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
50
|
Shikano N, Kotani T, Nakajima S, Ogura M, Nakazawa S, Sagara JI, Kobayashi M, Baba T, Yamaguchi N, Kubota N, Kawai K. Radioiodinated 4-iodo-l-meta-tyrosine, a system L selective artificial amino acid: molecular design and transport characterization in Chinese hamster ovary cells (CHO-K1 cells). Nucl Med Biol 2010; 37:903-10. [DOI: 10.1016/j.nucmedbio.2010.06.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2010] [Revised: 04/28/2010] [Accepted: 06/03/2010] [Indexed: 11/30/2022]
|